Abstract
A significant correlation has been shown between the binding antibody responses against original severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein and vaccine efficacy of 4 approved coronavirus disease 2019 vaccines. We therefore assessed the immune response against original SARS-CoV-2 elicited by the adjuvanted S-Trimer vaccine, SCB-2019 + CpG/alum, in the same assay and laboratory. Responses to SCB-2019 were comparable or superior for antibody to original and Alpha variant when compared with 4 approved vaccines. The comparison accurately predicted success of the recently reported efficacy trial of SCB-2019 vaccine. Immunogenicity comparisons to original strain and variants of concern should be considered as a basis for authorization of vaccines.
Keywords: COVID-19; immunogenicity; vaccine; variants of concern.
【저자키워드】 COVID-19, Vaccine, immunogenicity, variants of concern, 【초록키워드】 coronavirus disease, SARS-CoV-2, Coronavirus disease 2019, Efficacy, coronavirus, immune response, immunogenicity, Trial, Vaccines, antibody, vaccine efficacy, variants of concern, variants, Spike protein, Laboratory, response, comparison, Alpha, Alpha variant, respiratory, correlation, alum, binding antibody, acute respiratory syndrome, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, authorization, SCB-2019, shown, predicted, reported, approved, comparable, elicited, responses against,